Huge Opportunity in Biotech: Follow the Smart Money & Industry Vets!
Some of the biotech sector’s most affluent and influential individuals are making a move from companies such as Deutsche Bank, Pfizer, AstraZeneca, Chase Pharmaceuticals & more to GT Biopharma Inc. (GTBP). This up-and-coming biotech company has a therapy pipeline that has attracted some of the industry’s most experienced leaders.
Halozyme Therapeutics, Inc. To Host First Quarter 2018 Financial Results Conference Call
Halozyme Therapeutics, Inc. , a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the first quarter 2018 on Thurs., May 10at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the first quarter ended March 31, 2018 following the close of trading.
BIOTECHSTOCKS.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $1,800,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending April. 30, 2018 to publicly disseminate information about (GTBP). We own zero shares. Full Disclaimer Here